87 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
acid alpha-glucosidase (GAA)
5 Pombiliti + Opfolda: An Innovative Approach to Pompe Disease Our scientists created a uniquely glycosylated and highly
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
AT-GAA: An Innovative Approach to Pompe Disease Our scientists created a uniquely glycosylated and highly phosphorylated ERT (cipaglucosidase alfa
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
phase of our journey to profitability and continue our mission to bring innovative new therapies to those living with rare diseases.”
“The evolution
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
to Great Britain (GB) approval, Pombiliti + Opfolda was granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP), a Priority … Innovative Medicines designation, as well as a positive scientific opinion under the Early Access to Medicines Scheme (EAMS). This accelerated
8-K
EX-99.1
bv0v3arcy9jh
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-99.1
epole h66wne9dlt6mti
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-99.1
iiiq s03yedka5i
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
EX-99.1
l9lhimctzxs2i9za
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
8-K
EX-99.1
05805z1wiqnifsqiv3
7 Nov 22
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
lhe1etg
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am
8-K
EX-99.1
cd53h7qtq
4 Aug 22
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
7:01am
8-K
EX-99.1
lvriqv
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
8-K
EX-99.2
fqp6e41n
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
8-K
EX-99.2
o8wc z77a2umfylxnd8
9 Nov 21
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
7:07am
8-K
EX-99.1
4c3oi
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
EX-99.2
tmd3nj
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am